Is Platinum Present in Blood and Urine from Treatment Givers during Hyperthermic Intraperitoneal Chemotherapy?

Background. In selected patients with peritoneal carcinomatosis (PC) originating from colorectal cancer (CRC) the high dosage of oxaliplatin (460 mg/m(2)) is recommended for hyperthermic intraperitoneal chemotherapy (HIPEC), which may be a health risk to those administering the drug. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Näslund Andréasson, Sara, Anundi, Helena, Thorén, Sig-Britt, Ehrsson, Hans, Mahteme, Haile
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902751/
https://www.ncbi.nlm.nih.gov/pubmed/20631909
http://dx.doi.org/10.1155/2010/649719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902751/
https://www.ncbi.nlm.nih.gov/pubmed/20631909
http://dx.doi.org/10.1155/2010/649719

Ejemplares similares